Quarter of adolescent U.S. girls received HPV vaccine

By Will Dunham

WASHINGTON (Reuters) - A quarter of girls aged 13-17 in the United States received Merck & Co’s Gardasil vaccine last year to protect against the human papillomavirus, which causes cervical cancer, the U.S. government said on Thursday.

A report by the Centers for Disease Control and Prevention provided the first look at how many adolescent girls are getting the vaccine, which won approval in June 2006 for preventing cervical cancer and genital warts in young women and girls aged 9-26.

Based on data on about 3,000 girls nationwide, the CDC said 25 percent had received at least one dose of the three-shot series in 2007, which translates to about 2.5 million girls.

Just under a third of adolescents got shots against potentially deadly meningitis, another new vaccine.

“It generally takes about seven or eight years before you can go from a new vaccine all the way to having 90 percent coverage rate, which would be the eventual target,” Dr. Lance Rodewald, head of the CDC’s division of immunization services, said during a conference call with reporters.

“In general, we’re quite pleased with the results at 25 percent. But it points out that we’ve got a long ways to go.”

Rodewald said the CDC did not have estimates on how many women up to age 26 were getting the vaccine.

Gardasil targets four strains of the human papillomavirus, also called HPV, a common sexually transmitted virus that causes genital warts and most cases of cervical cancer.  Continued…


Related Posts:

LONDON (Reuters) - A study of Merck & Co Inc’s cervical cancer vaccine Gardasil found that allergic reactions were uncommon and most young women can tolerate subsequent doses, Australian researchers said on Wednesday. The research involved 25 Australian girls with suspected hypersensitivity to the vaccine which was administered as part of a national immunization program to

Full Post: Allergic reactions to Gardasil uncommon: study

By Lewis Krauskopf and Ransdell Pierson NEW YORK (Reuters) - U.S. health regulators have again withheld approval for the use of Merck & Co Inc’s Gardasil cervical cancer vaccine by women aged 27 to 45, asking for longer-term clinical data, the drugmaker said on Friday. The U.S. Food and Drug Administration recommended Merck submit data when a

Full Post: Gardasil again denied approval for women 27-45

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - A vaccine designed to protect women and girls from cervical cancer caused by a wart virus may protect men, too, maker Merck and Co reported on Thursday. The Gardasil vaccine was 90 percent effective in preventing lesions, mostly sexually transmitted warts, caused by the virus in men,

Full Post: Merck vaccine protects men from wart virus, too

NEW YORK (Reuters) - U.S. health regulators want longer-term data on the use of Merck & Co’s Gardasil cervical cancer vaccine in an older group of women before they will approve the vaccine for those women, the drugmaker said on Friday. The U.S. Food and Drug Administration has issued a second complete response letter to Merck

Full Post: More data sought for Merck’s Gardasil in older women

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - Three studies published on Wednesday add to evidence that circumcision can protect men from the deadly AIDS virus and the sexually transmitted virus that causes cervical cancer. The reports in the Journal of Infectious Diseases are likely to add to the debate over whether men — and

Full Post: Male circumcision lowers cervical cancer risk: study

Site Navigation

Most Read



  • kinwrite.com@gmail.com